Business Description
Royalty Pharma PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BMVP7Y09
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.2 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.94 | |||||
Debt-to-EBITDA | 3.25 | |||||
Interest Coverage | 7.97 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.01 | |||||
Beneish M-Score | -3.03 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.6 | |||||
3-Year EBITDA Growth Rate | -14.5 | |||||
3-Year EPS without NRI Growth Rate | 30.7 | |||||
3-Year FCF Growth Rate | -2.9 | |||||
3-Year Book Growth Rate | 5.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 3.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.37 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 0.23 | |||||
9-Day RSI | 5.24 | |||||
14-Day RSI | 16.16 | |||||
6-1 Month Momentum % | -6.04 | |||||
12-1 Month Momentum % | -23.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.9 | |||||
Quick Ratio | 7.9 | |||||
Cash Ratio | 7.65 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.86 | |||||
Dividend Payout Ratio | 0.4 | |||||
3-Year Dividend Growth Rate | 38.7 | |||||
Forward Dividend Yield % | 2.91 | |||||
5-Year Yield-on-Cost % | 2.86 | |||||
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | 6.74 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 63.37 | |||||
Net Margin % | 48.2 | |||||
FCF Margin % | 127.34 | |||||
ROE % | 18.59 | |||||
ROA % | 6.82 | |||||
ROIC % | 9.93 | |||||
ROCE % | 11.87 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 11.06 | |||||
Forward PE Ratio | 8.09 | |||||
PE Ratio without NRI | 13.97 | |||||
PS Ratio | 7.14 | |||||
PB Ratio | 1.91 | |||||
Price-to-Tangible-Book | 1.91 | |||||
Price-to-Free-Cash-Flow | 5.63 | |||||
Price-to-Operating-Cash-Flow | 5.63 | |||||
EV-to-EBIT | 9.2 | |||||
EV-to-Forward-EBIT | 7.91 | |||||
EV-to-EBITDA | 9.2 | |||||
EV-to-Forward-EBITDA | 7.91 | |||||
EV-to-Revenue | 7.37 | |||||
EV-to-Forward-Revenue | 6.68 | |||||
EV-to-FCF | 5.81 | |||||
Price-to-Graham-Number | 1.09 | |||||
Earnings Yield (Greenblatt) % | 10.87 | |||||
FCF Yield % | 23.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Royalty Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 41,386.485 | ||
EPS (TTM) (MXN) | 44.277 | ||
Beta | -0.27 | ||
Volatility % | 23.83 | ||
14-Day RSI | 16.16 | ||
14-Day ATR (MXN) | 0.943323 | ||
20-Day SMA (MXN) | 490 | ||
12-1 Month Momentum % | -23.79 | ||
52-Week Range (MXN) | 463.34 - 653.5 | ||
Shares Outstanding (Mil) | 446.69 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Royalty Pharma PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Royalty Pharma PLC Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
Royalty Pharma PLC Frequently Asked Questions
What is Royalty Pharma PLC(MEX:RPRX)'s stock price today?
When is next earnings date of Royalty Pharma PLC(MEX:RPRX)?
Does Royalty Pharma PLC(MEX:RPRX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |